Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01215942 · ClinicalTrials.gov registry record · Phase 3
An Open Label Study for Participants With Rheumatoid Arthritis
A Phase 3 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,086
- Enrollment target
NCT01215942 is a Phase 3 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 1,086 participants.
The verdict
NCT01215942, a Phase 3 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,086 participants
- Enrollment target
Study Summary
The primary purpose of this study is to help answer if LY2127399 is safe and effective during long-term treatment in participants with Rheumatoid Arthritis. This study is comprised of 2 periods: Period 1: Unblinded treatment for up to 240 weeks for participants who enroll from Study H9B-MC-BCDO (BCDO) (NCT01202760) or Study H9B-MC-BCDV (BCDV) (NCT01202773) or up to 168 weeks for participants who enroll from Study H9B-MC-BCDM (BCDM) (NCT01198002). Period 2: 48-week post-treatment follow-up
Interventions
- DRUG LY2127399
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,086 participants |
| Start Date | 2011-06 |
| Est. Completion | 2014-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01215942
The ClinicalTrials.gov registry entry for NCT01215942 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,086 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LY2127399 is the first listed.
NCT01215942 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01215942 about?
NCT01215942 is a clinical study titled "An Open Label Study for Participants With Rheumatoid Arthritis". The primary purpose of this study is to help answer if LY2127399 is safe and effective during long-term treatment in participants with Rheumatoid Arthritis. This study is comprised of 2 periods: Period 1: Unblinded treatment for up to 240 weeks for participants who enroll from Study H9B-MC-BCDO (B...
What is the current status of trial NCT01215942?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,086 participants. The study started on 2011-06. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01215942?
The interventions under investigation include: LY2127399 (DRUG).
Who is sponsoring clinical trial NCT01215942?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.